WEBULL
WebtradeDownload

Is Centene (CNC) A Bargain On Its Q2 Beat And Higher Outlook?

Simply Wall St · 2d ago

Why Centene stock is moving now

Centene (CNC) is back on investors’ radar after a strong Q2 earnings beat that paired solid revenue figures with a more upbeat full year outlook and indicated progress toward profitability.

The reaction was quick. Shares climbed 4.6% following the release and recently traded around $67.03, providing a fresh reference point against the company’s updated guidance and ongoing turnaround efforts.

That Q2 surprise comes on top of a sharp rebound in Centene’s 54.57% year-to-date share price return, even though the stock has eased in recent sessions and produced a 1-year total shareholder return of 107.92%.

Investors have been weighing that strong recent run against a softer 3-year total shareholder return of a 3.64% decline and a modest 5-year total shareholder return of 6.22%, while keeping an eye on smaller headlines such as new maternal health grants at Fidelis Care and the incoming Chief Information Officer as possible longer-term supports for the investment story.

Capitalize on Centene's renewed momentum by lining it up against a curated 17 high quality undiscovered gems that may be flying under the radar.

Centene has just sprinted higher on strong Q2 news, while the longer track record tells a slower story. Is that recent surge already in the price, or does the current valuation still leave meaningful room before you consider waiting?

Most Popular Narrative: 9.9% Undervalued

Centene's most followed valuation narrative pegs fair value at $71.67 per share versus the last close of $64.58, framing the recent rally as still short of that target.

Centene's Medicaid business is expected to see margin recovery as rate adjustments align better with member acuity, which could improve Medicaid-related revenue and net margins. Overall strength and competitiveness in winning Medicaid contracts, such as the fully integrated D-SNP in Illinois and Medicaid expansion into rural Nevada, may drive future revenue growth and market share.

Read the complete narrative.

Want to understand why this narrative still sees upside for Centene at current prices? The core thesis leans on a shift from loss making to consistently profitable operations, paired with a future earnings multiple that sits below many healthcare peers. Curious which revenue and margin assumptions have to hold for that fair value to stack up? The full story ties those moving parts together in a way the headline price alone cannot.

Result: Fair Value of $71.67 (UNDERVALUED)

Have a read of the narrative in full and understand what's behind the forecasts.

Still, Centene’s story can change quickly if Medicaid rate decisions break unfavorably or if high specialty drug costs continue to squeeze already thin healthcare margins.

Find out about the key risks to this Centene narrative.

Next Steps

Mixed messages in the Centene story so far. If you want to move quickly and reach your own judgment, start by weighing the 3 key rewards and 1 important warning sign.

Looking for more Centene style investment ideas?

Centene gives you a useful reference point, but your next strong idea probably comes from widening the search beyond a single ticker.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.